---
layout: default
title: Sodium Chloride
parent: 僅模型預測 (L5)
nav_order: 410
evidence_level: L5
indication_count: 10
---

# Sodium Chloride
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Sodium Chloride: From General Physiological Use to Breast Fibrocystic Disease

## One-Sentence Summary

Sodium chloride (DrugBank DB09153) has no specific licensed therapeutic indication on record in this dataset — it is not currently marketed in South Africa. The TxGNN model predicts a possible association with **Breast Fibrocystic Disease**, but this is currently supported only by one non-interventional diagnostic-imaging trial and **7 publications**, none of which test saline as a treatment for this condition, so the signal should be treated as exploratory rather than actionable.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | No specific licensed indication on record (product not currently marketed in South Africa) |
| Predicted New Indication | Breast Fibrocystic Disease |
| TxGNN Prediction Score | 96.79% |
| Evidence Level | L5 |
| South Africa Market Status | Not marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data for sodium chloride is not available, and no formal original indication is recorded for this product in this dataset. Sodium chloride is a basic electrolyte/isotonic solution used broadly across medicine (e.g., as an IV fluid, diluent, or irrigation solution), rather than a drug with a single defined pharmacological indication — which limits how meaningful a mechanistic comparison to breast fibrocystic disease can be.

The supporting literature identified for this prediction largely describes the **biochemical composition of breast cyst fluid** (sodium, chloride, and potassium concentrations, Na+/K+ ratios, and related proteins), rather than any therapeutic effect of administering sodium chloride. In other words, the model appears to be picking up on the fact that sodium and chloride ions are naturally present in and studied within breast cyst fluid — a correlative/descriptive relationship, not evidence of causal treatment benefit. The one associated clinical trial (NCT02887937) is a diagnostic ultrasound imaging study and does not test any saline intervention.

Given this, the mechanistic case for repurposing sodium chloride as a treatment for breast fibrocystic disease is weak and indirect at this stage, consistent with the model's own L5 (prediction-only) evidence grading.

---

## Clinical Trial Evidence

| Trial Number | Phase | Status | Enrollment | Key Findings |
|---------|------|------|------|---------|
| [NCT02887937](https://clinicaltrials.gov/study/NCT02887937) | N/A | Completed | 135 | Evaluated contrast-enhanced ultrasound (CEUS) to assess whether biopsy is necessary for suspicious cystic breast masses; a diagnostic-imaging study, not a treatment trial, and does not test sodium chloride as a therapeutic agent. |

---

## Literature Evidence

| PMID | Year | Type | Journal | Key Findings |
|------|-----|------|------|---------|
| [2015669](https://pubmed.ncbi.nlm.nih.gov/2015669/) | 1991 | Cohort | Clinical Chemistry | Classified breast cyst types by GCDFP-70 protein (albumin) content in cyst fluid — biochemical characterization, not treatment. |
| [2140797](https://pubmed.ncbi.nlm.nih.gov/2140797/) | 1990 | Cohort | Eur J Surg Oncol | Classified breast cysts (Type I/II) by intracystic Na+/K+ ratio, chloride, glucose, and hormone levels. |
| [9375824](https://pubmed.ncbi.nlm.nih.gov/9375824/) | 1997 | Cohort | Nephron | Compared electrolyte and amino acid composition of kidney cyst fluid vs. breast cyst fluid. |
| [3232934](https://pubmed.ncbi.nlm.nih.gov/3232934/) | 1988 | Case Series | Annals of Plastic Surgery | 9-year experience with saline-inflatable prostheses for breast reconstruction after subcutaneous mastectomy — reconstruction, not fibrocystic disease treatment. |
| [10797312](https://pubmed.ncbi.nlm.nih.gov/10797312/) | 2000 | Basic Science | Journal of Cellular Physiology | Studied intracellular pH regulation in malignant vs. non-malignant breast cell lines; unrelated to saline therapy. |
| [3369685](https://pubmed.ncbi.nlm.nih.gov/3369685/) | 1988 | Basic Science | Analytical Biochemistry | Described a collagen fractionation technique using alkaline potassium chloride in breast tissue samples. |
| [23073330](https://pubmed.ncbi.nlm.nih.gov/23073330/) | 2012 | Case Report | American Journal of Surgical Pathology | Reported a rare lymphoma arising in association with a saline breast implant — a safety signal, not efficacy evidence. |

---

## South Africa Market Information

No SAHPRA registrations are recorded for this product in this dataset (market status: Not marketed; total licenses: 0).

---

## Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
Although the TxGNN prediction score is high, the evidence level is L5 — the only associated clinical trial is a diagnostic-imaging study, and all supporting literature describes cyst fluid biochemistry rather than any therapeutic effect of sodium chloride on breast fibrocystic disease. There is currently no direct interventional evidence to support this indication.

**To proceed, the following is needed:**
- Mechanism of action / pharmacological classification data for sodium chloride in this context (currently a data gap)
- SAHPRA-approved PI warnings, precautions, and contraindications (currently a blocking data gap)
- Direct interventional clinical evidence testing sodium chloride as a treatment for breast fibrocystic disease
- Confirmation of South African market/registration status, since the product is currently not marketed
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

